Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: SXC-2023
DRUG: Placebo oral capsule

Sponsor

Promentis Pharmaceuticals, Inc.

Collaborators

[object Object]